Literature DB >> 28151489

Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing.

Paul Kuentz1,2,3, Judith St-Onge1,2,4, Yannis Duffourd1,2, Jean-Benoît Courcet2,5, Virginie Carmignac1,2, Thibaud Jouan1,2, Arthur Sorlin1,2, Claire Abasq-Thomas6, Juliette Albuisson7, Jeanne Amiel8, Daniel Amram9, Stéphanie Arpin10, Tania Attie-Bitach11, Nadia Bahi-Buisson8, Sébastien Barbarot12, Geneviève Baujat8, Didier Bessis13, Olivia Boccara14, Maryse Bonnière11, Odile Boute15, Anne-Claire Bursztejn16, Christine Chiaverini17, Valérie Cormier-Daire8, Christine Coubes18, Bruno Delobel19, Patrick Edery20, Salima El Chehadeh21, Christine Francannet22, David Geneviève18, Alice Goldenberg23, Damien Haye24, Bertrand Isidor25, Marie-Line Jacquemont26, Philippe Khau Van Kien27, Didier Lacombe28, Ludovic Martin29, Jelena Martinovic30, Annabel Maruani31, Michèle Mathieu-Dramard32, Juliette Mazereeuw-Hautier33, Caroline Michot8, Cyril Mignot34, Juliette Miquel35, Fanny Morice-Picard28, Florence Petit15, Alice Phan36, Massimiliano Rossi20, Renaud Touraine37, Alain Verloes38, Marie Vincent25, Catherine Vincent-Delorme15, Sandra Whalen39, Marjolaine Willems18, Nathalie Marle1,2,40, Daphné Lehalle1,2,5, Julien Thevenon1,2,5, Christel Thauvin-Robinet1,2,5, Smaïl Hadj-Rabia14, Laurence Faivre1,2,5, Pierre Vabres1,2,41, Jean-Baptiste Rivière1,2,4,42.   

Abstract

PURPOSE: Postzygotic activating mutations of PIK3CA cause a wide range of mosaic disorders collectively referred to as PIK3CA-related overgrowth spectrum (PROS). We describe the diagnostic yield and characteristics of PIK3CA sequencing in PROS.
METHODS: We performed ultradeep next-generation sequencing (NGS) of PIK3CA in various tissues from 162 patients referred to our clinical laboratory and assessed diagnostic yield by phenotype and tissue tested.
RESULTS: We identified disease-causing mutations in 66.7% (108/162) of patients, with mutant allele levels as low as 1%. The diagnostic rate was higher (74%) in syndromic than in isolated cases (35.5%; P = 9.03 × 10-5). We identified 40 different mutations and found strong oncogenic mutations more frequently in patients without brain overgrowth (50.6%) than in those with brain overgrowth (15.2%; P = 0.00055). Mutant allele levels were higher in skin and overgrown tissues than in blood and buccal samples (P = 3.9 × 10-25), regardless of the phenotype.
CONCLUSION: Our data demonstrate the value of ultradeep NGS for molecular diagnosis of PROS, highlight its substantial allelic heterogeneity, and confirm that optimal diagnosis requires fresh skin or surgical samples from affected regions. Our findings may be of value in guiding future recommendations for genetic testing in PROS and other mosaic conditions.Genet Med advance online publication 02 February 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28151489     DOI: 10.1038/gim.2016.220

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  33 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

2.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.

Authors:  Turgut Dogruluk; Yiu Huen Tsang; Maribel Espitia; Fengju Chen; Tenghui Chen; Zechen Chong; Vivek Appadurai; Armel Dogruluk; Agna Karina Eterovic; Penelope E Bonnen; Chad J Creighton; Ken Chen; Gordon B Mills; Kenneth L Scott
Journal:  Cancer Res       Date:  2015-12-01       Impact factor: 12.701

3.  PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.

Authors:  Laura A Jansen; Ghayda M Mirzaa; Gisele E Ishak; Brian J O'Roak; Joseph B Hiatt; William H Roden; Sonya A Gunter; Susan L Christian; Sarah Collins; Carissa Adams; Jean-Baptiste Rivière; Judith St-Onge; Jeffrey G Ojemann; Jay Shendure; Robert F Hevner; William B Dobyns
Journal:  Brain       Date:  2015-02-25       Impact factor: 13.501

Review 4.  Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation.

Authors:  L G Biesecker; R Happle; J B Mulliken; R Weksberg; J M Graham; D L Viljoen; M M Cohen
Journal:  Am J Med Genet       Date:  1999-06-11

5.  Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.

Authors:  Kyle C Kurek; Valerie L Luks; Ugur M Ayturk; Ahmad I Alomari; Steven J Fishman; Samantha A Spencer; John B Mulliken; Margot E Bowen; Guilherme L Yamamoto; Harry P W Kozakewich; Matthew L Warman
Journal:  Am J Hum Genet       Date:  2012-05-31       Impact factor: 11.025

6.  Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.

Authors:  Ghayda M Mirzaa; Jean-Baptiste Rivière; William B Dobyns
Journal:  Am J Med Genet C Semin Med Genet       Date:  2013-04-16       Impact factor: 3.908

7.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

8.  PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution.

Authors:  Ghayda Mirzaa; Andrew E Timms; Valerio Conti; Evan August Boyle; Katta M Girisha; Beth Martin; Martin Kircher; Carissa Olds; Jane Juusola; Sarah Collins; Kaylee Park; Melissa Carter; Ian Glass; Inge Krägeloh-Mann; David Chitayat; Aditi Shah Parikh; Rachael Bradshaw; Erin Torti; Stephen Braddock; Leah Burke; Sondhya Ghedia; Mark Stephan; Fiona Stewart; Chitra Prasad; Melanie Napier; Sulagna Saitta; Rachel Straussberg; Michael Gabbett; Bridget C O'Connor; Catherine E Keegan; Lim Jiin Yin; Angeline Hwei Meeng Lai; Nicole Martin; Margaret McKinnon; Marie-Claude Addor; Luigi Boccuto; Charles E Schwartz; Agustina Lanoel; Robert L Conway; Koenraad Devriendt; Katrina Tatton-Brown; Mary Ella Pierpont; Michael Painter; Lisa Worgan; James Reggin; Raoul Hennekam; Karen Tsuchiya; Colin C Pritchard; Mariana Aracena; Karen W Gripp; Maria Cordisco; Hilde Van Esch; Livia Garavelli; Cynthia Curry; Anne Goriely; Hulya Kayserilli; Jay Shendure; John Graham; Renzo Guerrini; William B Dobyns
Journal:  JCI Insight       Date:  2016-06-16

9.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

10.  Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.

Authors:  Anna C Thomas; Zhiqiang Zeng; Jean-Baptiste Rivière; Ryan O'Shaughnessy; Lara Al-Olabi; Judith St-Onge; David J Atherton; Hélène Aubert; Lorea Bagazgoitia; Sébastien Barbarot; Emmanuelle Bourrat; Christine Chiaverini; W Kling Chong; Yannis Duffourd; Mary Glover; Leopold Groesser; Smail Hadj-Rabia; Henning Hamm; Rudolf Happle; Imran Mushtaq; Jean-Philippe Lacour; Regula Waelchli; Marion Wobser; Pierre Vabres; E Elizabeth Patton; Veronica A Kinsler
Journal:  J Invest Dermatol       Date:  2016-01-14       Impact factor: 8.551

View more
  30 in total

1.  Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients.

Authors:  Andrew M Piacitelli; Dana M Jensen; Heather Brandling-Bennett; Megan Mariner Gray; Maneesh Batra; Juliane Gust; Ameet Thaker; Catherine Paschal; Karen Tsuchiya; Colin C Pritchard; Jonathan Perkins; Ghayda M Mirzaa; James T Bennett
Journal:  Am J Med Genet A       Date:  2018-07-31       Impact factor: 2.802

2.  Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations.

Authors:  Kaitlyn Zenner; Chi Vicky Cheng; Dana M Jensen; Andrew E Timms; Giridhar Shivaram; Randall Bly; Sheila Ganti; Kathryn B Whitlock; William B Dobyns; Jonathan Perkins; James T Bennett
Journal:  JCI Insight       Date:  2019-11-01

3.  Segmental Ipsilateral Odontognathic Dysplasia (Mandibular Involvement in Segmental Odontomaxillary Dysplasia?) and Identification of PIK3CA Somatic Variant in Lesional Mandibular Gingival Tissue.

Authors:  Tanya M Gibson; Keith Rafferty; Elyse Ryan; Arupa Ganguly; Ioannis G Koutlas
Journal:  Head Neck Pathol       Date:  2020-06-04

4.  Diagnostic Utility of Next-Generation Sequencing for Disorders of Somatic Mosaicism: A Five-Year Cumulative Cohort.

Authors:  Samantha N McNulty; Michael J Evenson; Meagan M Corliss; Latisha D Love-Gregory; Molly C Schroeder; Yang Cao; Yi-Shan Lee; Beth A Drolet; Julie A Neidich; Catherine E Cottrell; Jonathan W Heusel
Journal:  Am J Hum Genet       Date:  2019-10-03       Impact factor: 11.025

5.  Clinical and Molecular Spectrum of Sporadic Vascular Malformations: A Single-Center Study.

Authors:  Andrea Diociaiuti; Roberta Rotunno; Elisa Pisaneschi; Claudia Cesario; Claudia Carnevale; Angelo Giuseppe Condorelli; Massimo Rollo; Stefano Di Cecca; Concetta Quintarelli; Antonio Novelli; Giovanna Zambruno; May El Hachem
Journal:  Biomedicines       Date:  2022-06-20

6.  Diffuse capillary malformation with overgrowth contains somatic PIK3CA variants.

Authors:  Jeremy A Goss; Dennis J Konczyk; Patrick Smits; Christopher L Sudduth; Joyce Bischoff; Marilyn G Liang; Arin K Greene
Journal:  Clin Genet       Date:  2020-01-27       Impact factor: 4.438

Review 7.  Overgrowth syndromes - clinical and molecular aspects and tumour risk.

Authors:  Frédéric Brioude; Annick Toutain; Eloise Giabicani; Edouard Cottereau; Valérie Cormier-Daire; Irene Netchine
Journal:  Nat Rev Endocrinol       Date:  2019-05       Impact factor: 43.330

8.  Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.

Authors:  M E Michel; D J Konczyk; K S Yeung; R Murillo; M P Vivero; A M Hall; D Zurakowski; D Adams; A Gupta; A Y Huang; B H Y Chung; M L Warman
Journal:  Clin Genet       Date:  2018-01-25       Impact factor: 4.438

Review 9.  A standard of care for individuals with PIK3CA-related disorders: An international expert consensus statement.

Authors:  Sofia Douzgou; Myfanwy Rawson; Eulalia Baselga; Moise Danielpour; Laurence Faivre; Alon Kashanian; Kim M Keppler-Noreuil; Paul Kuentz; Grazia M S Mancini; Marie-Cecile Maniere; Victor Martinez-Glez; Victoria E Parker; Robert K Semple; Siddharth Srivastava; Pierre Vabres; Marie-Claire Y De Wit; John M Graham; Jill Clayton-Smith; Ghayda M Mirzaa; Leslie G Biesecker
Journal:  Clin Genet       Date:  2021-07-16       Impact factor: 4.296

Review 10.  A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.

Authors:  Guillaume Canaud; Adrienne M Hammill; Denise Adams; Miikka Vikkula; Kim M Keppler-Noreuil
Journal:  Orphanet J Rare Dis       Date:  2021-07-08       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.